Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir + Sofosbuvir in HCV Genotype 4
NCT02253550Phase 2Completed
- Start
- Oct 2014
- Primary completion
- Jan 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of simeprevir in hepatitis C (HCV). Started Oct 2014; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02253550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253550.